4-1BB x CEACAM5

Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstrating strong inhibition of tumor growth and well-tolerated safety profile IND for LM-299 in the US expected to be submitted in the second half of 2024 Proceeds from the completed Series C1 financing will be primarily used to advance the clinical development of the Company's pipeline, including lead candidates LM-299 (anti-PD-1/VEGF BsAb), LM-302 (anti-CLDN 18.2 ADC) and LM-108 (anti-CCR8 mAb) Financing led by Sino Biopharmaceuticals, with participation of new and current investors SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- LaNova Medicines Limited ("LaNova" or "The Company"), a privately-held clinical-stage innovation-driven biotech specializing in ADCs and immuno-oncology, announced the initiation of its Phase 1 clinical trial of LM-299, an anti-PD-1/VEGF BsAb, in China for advanced solid tumors and the successful completion of its $42 million Series C1 financing. Founded in September 2019, LaNova's R&D engine is based on three proprietary platforms adept at tackling challenging targets and versatile modality development, which has so far enabled the in-house development of more than ten innovative programs, including monoclonal antibodies, ADCs and bispecific antibodies. Following promising preclinical results demonstrating LM-299's strong inhibition of tumor growth in hPBMCs-humanized mice and well tolerated safety profile in NHP GLP tox study, LaNova has initiated its first-in-human clinical trial in China for advanced solid tumors. LaNova is planning to initiate an additional Phase 1 clinical trial in the US and expects to submit an IND in the second half of 2024. The completed Series C1 financing was led by Sino Biopharmaceuticals and included participation from new investors Pudong Innovation Investment and Zhangjiang Haoheng, and existing investors, Qiming Venture Partners and Shanghai Healthcare Capital. Zhong Lun Law Firm acted as the legal advisor for this round of financing. LaNova has recently initiated its Series C2 financing round. Proceeds will be primarily used to advance the clinical development of the Company's pipeline, including lead candidates: LM-302 (anti-CLDN 18.2 ADC): ongoing Phase III registrational clinical trial in China for gastric cancers, making it one of the top three candidates globally in terms of development progress for this target; US Phase II trial expected to start in H2 2025 LM-108 (anti-CCR8 mAb): ongoing Phase II clinical trials in China for multiple solid tumors, making it one of the top three most advanced projects worldwide targeting CCR8; US Phase II trial expected to start in H2 2024 LM-299 (anti-PD-1/VEGF BsAb): Phase I clinical trial in China is currently enrolling patients for advanced solid tumors Dr. Crystal Qin, LaNova's founder, chairwoman and CEO, stated: "Since its establishment, LaNova has been dedicated to original innovation, with a focus on the tumor microenvironment and the development of tumor-specific targeted ADCs and immune-modulating biologics. We have established a robust pipeline of differentiated innovative drugs, with independent intellectual property rights and profiles that are competitive on a global scale. We are thrilled to have initiated our Phase 1 trial for LM-299 and completed our series C1 financing round. We are especially grateful for the continued support and confidence of our new and long-standing investors during this challenging period for pharmaceutical investments. Proceeds from this financing will allow us to expedite the development of our late-stage clinical programs, LM-302 and LM-108, moving us closer to market approval. We will also accelerate the clinical development of LM-299, which is currently in Phase 1 clinical trials with best-in-class potential. We look forward to strengthening our partnerships across the industry and enhancing our self-sustainability through business development collaborations. Together, we aspire to bring China's innovative drugs to a global stage, ultimately providing high-quality treatment solutions to more patients and promoting healthier lives worldwide." About LaNova Medicines Ltd. Founded in September 2019, LaNova Medicines Ltd. is a privately held biotech company headquartered in Shanghai. With the mission of "Care for life, Dedicate to innovation", the Company focuses on discovering novel biologic therapies in the fields of ADC and Immuno-Oncology, with a commitment to developing best-in-class or first-in-class therapies that address significant unmet medical needs. LaNova's robust portfolio is made possible by an industry-leading R&D engine, which includes three distinct platform: a proprietary antibody platform capable of generating antibodies against a range of targets, including multi-transmembrane proteins and GPCRs; a next-generation ADC platform that utilizes proprietary payload and linker technologies to produce highly differentiated ADCs; and a modular 4-1BB-based T-cell engager (TCE) platform for developing bispecific antibodies targeting distinct tumor-associated antigens (TAAs). Currently, LaNova's pipeline includes 6 clinical-stage assets and over 10 innovative preclinical programs. Its leading clinical-stage candidates include LM-302, a differentiated anti-Claudin 18.2 ADC in Phase 3 development in China; LM-108, a potential best-in-class CCR8-targeting monoclonal antibody in Phase 2 in China; and several Phase 1 programs including LM-299 (anti-PD-1/VEGF bispecific antibody), LM-101 (anti-SIPRα monoclonal antibody), LM-305 (anti-GPRC5D ADC with global rights licensed to AstraZeneca), and LM-24C5 (anti-CEACAM5 bispecific antibody). Through internal R&D innovation and strategic external partnerships, LaNova is committed to advancing its pipeline to benefit patients worldwide. LaNova's key clinical stage pipeline programs and expected upcoming milestones LM-299 (Anti-PD-1/VEGF bispecific antibody) LM-299 is a bispecific antibody developed by LaNova that targets both PD-1 and VEGF. This innovative therapy can simultaneously block the PD-1/PD-L1 and VEGF/VEGFR signaling pathways, achieving a synergistic anti-tumor effect that combines tumor immunity with anti-angiogenesis. LM-299 features a differentiated molecular design, comprising an anti-VEGF antibody linked to a C-terminal anti-PD-1 antibody, which ensures high expression, optimal druggability, and best-in-class potential. Preliminary studies have demonstrated that LM-299 effectively inhibits the PD-1 and VEGF signaling pathways, enhancing anti-tumor efficacy. Additionally, toxicological and pharmacokinetic evaluations indicated that LM-299 possesses a superior safety profile. As a promising cornerstone therapy for the next generation of tumor immunotherapy, LM-299 can be combined with various treatment modalities, including immuno-oncology drugs, small molecule targeted therapies, antibody-drug conjugates and T cell activators, thereby significantly broadening the market potential for LM-299-based combination therapies. The Phase I clinical trial for LM-299 is currently enrolling patients. LM-302 (Anti-Claudin 18.2 ADC) LM-302 is an innovative antibody-drug conjugate (ADC) developed by LaNova, targeting Claudin 18.2, using the company's proprietary multi-transmembrane protein antibody discovery platform. The drug consists of a Claudin 18.2-specific antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable VC-PAB linker. Claudin 18.2 is a transmembrane protein highly expressed in gastrointestinal cancers, including gastric, gastroesophageal junction, pancreatic, and biliary tract cancers. Treatments targeting Claudin 18.2 have shown significant anti-cancer potential in clinical settings. In the first quarter of 2024, LM-302 entered a Phase III registrational clinical trial in China, making it one of the top three candidates globally in terms of development progress for this target. Additionally, Phase II clinical trials exploring LM-302 in combination with PD-1 monoclonal antibodies are actively underway. Phase III GC/GEJ monotherapy: interim data readout expected in H2 2025 Phase II 1L GC/GEJ combination study in US to be initiated in H2 2025 LM-108 (Anti-CCR8 monoclonal antibody) LM-108 is a monoclonal antibody targeting CCR8, independently developed by LaNova using its proprietary multi-transmembrane protein antibody discovery platform. LM-108 effectively eliminates tumor-infiltrating regulatory T cells (Tregs) via antibody-dependent cell-mediated cytotoxicity (ADCC), while sparing peripheral Tregs. This enhances the immune system's ability to attack tumor cells. Due to the specificity of CCR8, many global pharmaceutical companies are pursuing this target. LaNova has advanced LM-108 to Phase II clinical trials, making it one of the top three most advanced projects worldwide targeting CCR8. Preliminary clinical data show that LM-108 has demonstrated excellent safety and efficacy across multiple solid tumor types with significant unmet clinical needs. LM-108 holds promise as a new immunotherapy option, particularly for patients with advanced tumors who have become resistant to PD-1 treatments. Phase III registrational trial to be initiated in China in H2 2024 Phase II combination trial to be initiated in US in H2 2024 SOURCE LaNova Medicines WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024 年 ESMO 年会正在进行中。根据 Insight 数据库，本届大会上有 30 多项双特异性抗体的临床研究数据入选，其中包括许多尚未获批的在研双抗新药，靶点涵盖 PD-L1/VEGFA、TIGIT/PD-1、CD3/STEAP1、CD20/CD47、CD3/CEACAM5、CD47/PD-L1、4-1BB/5T4、DLL3/CD3、4-1BB/CLDN-18.2、EGFR/FCGR3A 等等。本文将分享其中 5 项首次披露临床数据的在研双抗研究，仅供读者参阅。 阿斯利康首次公布TIGIT/PD-1 双抗胃癌研究数据 Rilvegostomig 是一种在研 PD-1 / TIGIT 双抗，全球和国内的最高研究进度均为 Ⅲ 期临床。本次大会上，阿斯利康首次公布了 Rilvegostomig (以下简称 Rilve) + 化疗治疗 HER2–局部晚期不可切除或转移性胃或胃食管交界腺癌的 GEMINI-Gastric (NCT05702229) 研究结果。 截图来源：ESMO 官网 在该研究中，患者接受 Rilve 750 mg Q3W IV + XELOX（奥沙利铂 + 卡培他滨）或 FOLFOX（奥沙利铂 + 5-FU + 亚叶酸）治疗。主要终点是 ORR（通过基线 PD-L1 综合阳性评分 (CPS) <5 vs ≥5 进行分析）和 6 个月时 PFS；次要终点是安全性。  在数据截止时（2023 年 12 月 27 日），40 名患者接受了 Rilve+ XELOX（n=27）或 Rilve + FOLFOX（n=13）治疗，并有机会进行≥3 个月的随访（2 次治疗期间扫描）；27 名患者（67.5%）正在接受治疗。72.5% 的患者为亚洲人，52.5% 的患者 ECOG PS 为 0。所有患者均患有 IV 期疾病且伴有远处转移。 有效性数据显示，未证实的 ORR 为 67.5%（PD-L1 CPS ≥5 和 CPS <5 的患者分别为 81.3% 和 59.1%），证实的 ORR 为 52.5%（详见下表）。所有患者均有疾病控制（客观反应或疾病稳定）；无原发性进展性疾病。 截图来源：ESMO 官网 所有患者均有治疗引起的不良事件 (TEAE) 和治疗相关 AE（TRAE，60.0% 与治疗相关）。最常见的 TEAE 是恶心、中性粒细胞计数减少和食欲下降。≥3 级 TEAE 发生率为 45.0%，TRAE 发生率为 37.5%（7.5% 与 Rilve  有关）。未发生与 Rilve 有关的严重 AE (SAE)，任何原因的 SAE 均未导致死亡。 研究认为，Rilve +化疗显示出初步疗效和可控的 AE。该研究正在进行中，阿斯利康会在未来提供更新的疗效数据。 BMS 首次公布 TCER 双抗 Ⅰ 期临床数据 IMA401 是一种新一代 TCER 双特异性抗体，最初由 Immatics 公司研发。BMS 在 2021 年与 Immatics 公司达成一项高达 9.2 亿美元的合作，获得了该药的全球独家许可。本届大会上，研究人员以口头报告形式首次公布了该药在 I 期剂量递增中的初始安全性、药代动力学和抗肿瘤活性数据。 截图来源：ESMO 官网 IMA401 结合了针对 HLA-A*02:01 呈递的 MAGEA4/8 肽的高亲和力 TCR 结构域、低亲和力 T 细胞募集抗体和用于延长半衰期的 Fc 部分。MAGEA4/8 在多种实体瘤中表达，包括鳞状非小细胞肺癌、头颈部鳞状细胞癌、膀胱癌、子宫癌、食道癌和卵巢癌、黑色素瘤等等。 这项正在进行的 1a/1b 期首次人体临床试验评估了 IMA401 对复发/难治性实体瘤患者的初步效果和安全性。HLA-A*02:01+ 和 MAGEA4/8+ 患者最初接受 一周一次治疗（QW），然后接受两周一次（Q2W）静脉输注 IMA401。研究主要目标是确定 MTD 和/或 RP2D，次要目标是安全性、耐受性、PK、初始抗肿瘤活性。 截至 2024 年 4 月 1 日，25 名接受过大量前期治疗的癌症患者接受了第一剂量水平（DL1-7、6.6 μg-2.5 mg）的 IMA401。IMA401 表现出可控的耐受性，最常见的（≥30%）治疗相关不良事件是短暂性淋巴细胞减少症（G1-4）和 CRS（G1/2）。在引入地塞米松预处理后，在 DL7 观察到的高级（G3/4）中性粒细胞减少症没有复发。未达到 MTD/RP2D，并且剂量递增研究正在进行中。中位终末半衰期为 15.0 天。 在剂量递增阶段接受治疗的疗效可评估患者中，55% (11/20) 的患者实现了疾病控制 (SD/PR)，其中包括卵巢癌、鳞状非小细胞肺癌、胃癌、头颈部鳞状细胞癌、黑色素瘤和神经内分泌癌患者。45% (9/20) 的患者靶病变缩小（中位数 -21.7%），其中 3 名患者在首次输注后 4+月、10+个月 和 11+ 个月时确认持续 PR。 综合上述数据，研究认为 IMA401 耐受性良好，其单药抗肿瘤活性通过持久的客观反应和疾病控制得到证实，半衰期延长促使患者在剂量递增期间每 2 周切换一次治疗。研究表示，这项正在进行的 1 期剂量递增试验的数据为下一代半衰期延长 TCER® 形式及其在多种实体瘤中的潜力提供了第一个临床 PoC。 普米斯首次公布 PD-L1/VEGFA 双抗 NSCLC II 期研究数据 PM8002（BNT327）是普米斯开发的一种 PD-L1 /VEGF-A 双抗。本届大会上，PM8002 联合化疗治疗 EGFR 突变非小细胞肺癌 (NSCLC) 患者的单臂 II 期研究入选了口头报告。2023 年 11 月，BioNTech 公司曾与普米斯达成一项超 10.55 亿美元的授权合作，获得了该药在大中华区之外的全球其它地区的开发、生产和商业化权利。 截图来源：ESMO 官网 在该研究中，患者接受 PM8002 加卡铂和培美曲塞 Q3W 治疗 4 个周期，随后接受 PM8002 和培美曲塞维持治疗。主要终点是 ORR（RECIST v1.1）。通过免疫组织化学法对 EGFR-TKI 治疗进展后采集的活检样本进行 PD-L1 表达分析，并根据肿瘤比例评分 (TPS) 分为阴性（<1%）、低表达（1 %至 49%）或高表达（≥50%）。 截至 2024 年 4 月 12 日，64 名患者接受了 PD-L1 TPS 检测：28 名为 TPS<1%，23 名 为 TPS 1%-49%，13 名为 TPS ≥50%。所有患者均可评估安全性和疗效。数据显示： 总体 ORR 为 54.7% (35/64)，DCR 为 95.3% (61/64)。PD-L1 TPS＜1% 组 ORR 为 35.7%，DCR 为 92.9%；TPS 1%-49% 组 ORR 为 56.5%，DCR 为 100%；TPS≥50% 组 ORR 为 92.3%，DCR 为 92.3%。  95.3% 的患者发生了任何级别的治疗相关不良事件 (TRAE)，54.7% 的患者发生了 3 级以上 TRAE。28.1% 的患者发生了任何级别的免疫相关 AE (irAE)，4.7%  的患者发生了 3 级以上 irAE。6 名患者因 TRAE 停止使用 PM8002 和/或化疗，其中 1 例 TRAE 相关死亡。 Insight 数据库显示，PM8002 是国内首个也是目前唯一一个进入 Ⅲ 期临床的 PD-L1 /VEGF 双抗，正在开展治疗三阴性乳腺癌的 Ⅲ 期研究。此外，该药也已在今年 7 月获 CDE 批准开展联合紫杉醇注射液对比化疗二线治疗免疫经治的小细胞肺癌的注册性 Ⅲ 期临床。 宜明昂科首次公布 CD47/PD-L1 双抗Ⅰ 期临床数据 IMM2520 是一种在研 CD47/PD-L1 双特异性抗体，正在国内开展Ⅰ期临床。本次大会上，宜明昂科公布了 IMM2520 的 Ⅰ 期研究结果，该研究旨在评估 IMM2520 对晚期实体瘤患者的安全性、RP2D/MTD 和抗肿瘤作用。IMM2520 每周给药一次，每 28 天为一个周期。本次大会展示的是剂量递增阶段的结果。 截图来源：ESMO 官网 截至 2024 年 4 月 4 日，18 名患者接受了 5 个剂量水平（从 0.1mpk 到 4mpk）的治疗。大多数患者 (61%) 之前接受过 ≥ 3 线全身抗肿瘤治疗，其中 9 名患者有 PD-(L)1 疗法治疗史。研究尚未观察到 DLT。所有患者均报告了治疗相关不良事件 (TRAE)，其中 10 名 (56%) 患者为 ≥ 3 级。任何级别最常见的 TRAE 是血小板减少、贫血、白细胞减少和输液相关反应 。≥ 3 级的最常见 TRAE 是淋巴细胞减少、血小板减少和厌食症。未观察到导致治疗停止的 AE。 在 11 名可评估疗效的患者中，在 2mpk 治疗后，小细胞肺癌 (SCLC) 患者中观察到 1 例未证实的部分缓解（之前接受过 2 种疗法，包括免疫疗法和 PD-L1 表达阴性）和 5 例病情稳定，其中包括 1 例宫颈癌 (肿瘤缩小 21.1%），1 例结直肠癌（肿瘤缩小 11.1%）。药效学生物标志物包括外周循环 CD3+T 细胞上的 CD47 靶标占有率 (TO)。CD47 TO 率较轻，呈剂量依赖性趋势。 研究认为，IMM2520 在评估剂量下表现出耐受性，并且在晚期实体瘤中表现出初步的抗肿瘤活性，尤其是对于 SCLC。目前该研究的剂量递增研究正在进行中。 2024 年 8 月，Instil Bio 公司曾与宜明昂科达成授权合作，Instil 全资子公司 SynBioTx 获得 IMM2510 和 CTLA4 单抗 IMM27M 在大中华区以外的全球其它地区开发和商业化权利。该项交易包括高达 5000 万美元的首付款及潜在近期付款，以及总计超过 20 亿美元的里程碑付款。 石药集团/康宁杰瑞首次公布 HER2 双抗+化疗胃癌 II 期数据 KN026 是石药集团旗下津曼特生物从康宁杰瑞引进的一种新型 HER2 靶向双抗，可结合 HER2 的两个不同结构域。本次大会上，石药集团首次公布了 KN026 与化疗联合治疗无法切除或转移性 HER2 阳性胃癌或胃食管癌 (GC/GEJC) 患者的 II 期研究数据（NCT05427383）。 截图来源：ESMO 官网 在这项多中心、开放标签、II 期研究中，接受含曲妥珠单抗方案一线治疗后，HER2 阳性 GC/GEJC 患者根据既往治疗情况由研究者酌情分配接受 KN026（30 mg/kg，D1，Q3W）+紫杉醇（175 mg/m2，D1，Q3W）或伊立替康（125 mg/m2，D1 和 D8，Q3W）治疗。主要终点是 IRC 确定的安全性和 ORR 。 在数据截止时（2024 年 3 月 26 日），39 名患者入组并接受了至少一剂治疗。34 名患者观察到 HER3+染色。分别有 35 名和 37 名患者符合 IRC 和研究者评估疗效的条件。 IRC 确认的 ORR为 40.0% (14例PR) ，  DCR 为 80.0% (8例SD)。研究者确认的 ORR 为 45.9%(17例PR)  ， DCR 为 81.1% (13例SD)。 中位缓解时间为 1.38 个月，缓解持续时间为 11.7 个月。中位无进展生存期为 8.6 个月，总生存期为 13.2 个月。 最常见的≥3 级 TRAE（≥5%）为中性粒细胞减少症、白细胞减少症、贫血、疲劳、腹泻、淋巴细胞减少症、发热性中性粒细胞减少症、低钾血症和咳嗽。未发生与治疗相关的死亡。未观察到新的安全信号。 研究认为，KN026 联合化疗对一线治疗后 HER2 阳性 GC/GEJC 患者具有良好的抗肿瘤疗效，且安全性良好。KN026 与化疗联合治疗的 III 期研究正在进行中。 封面来源：站酷海洛 Plus 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。 编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验 点击阅读原文，立刻解锁！

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new platform license agreements in the first quarter, bringing our total active partners to 80, net of attrition,” said Matt Foehr, Chief Executive Officer of OmniAb. “We have built our company upon a differentiated suite of technologies and a highly scalable and leverageable business model, and our growth during the past 18 months reflects the strength of our offering to the industry. We’re off to a strong start in 2024 and we look forward to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first commercial sale of TECVAYLI® (teclistamab) in the EU and lower service revenue in the 2024 period as a result of the completion of discovery work on certain ion channel programs. Research and development expense was $14.6 million for the first quarter of 2024, compared with $13.8 million for the same period in 2023, with the increase primarily due to higher personnel costs. General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023. Net loss for the first quarter of 2024 was $19.0 million, or $0.19 per share, compared with a net loss of $6.1 million, or $0.06 per share, for the same period in 2023. As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million. 2024 Financial Guidance OmniAb continues to expect operating expense in 2024 to be approximately the same as in 2023, as the Company is now staffed and resourced to leverage the future growth of the business. OmniAb continues to expect its cash use in 2024 to be relatively similar to its cash use in 2023, excluding the $35 million TECVAYLI milestone payment received in 2023. Given the expected progression of the existing partnered pipeline, OmniAb expects its cash use in 2025 to be substantially lower than in 2024. OmniAb’s current cash balance and cash from operations are expected to provide sufficient capital to fund operations for the foreseeable future. First Quarter 2024 and Recent Business Highlights During the first quarter of 2024, OmniAb signed three new license agreements including ImmunoBiochem Corporation, the University of Georgia and a stealth Boston-based venture-backed start-up. As of March 31, 2024, the Company had 80 active partners and 327 active programs, including 31 OmniAb-derived programs in clinical development or being commercialized. First quarter 2024 and recent partner highlights include the following: Batoclimab Immunovant reported that global Phase 3 clinical trials of batoclimab (anti-FcRn) in myasthenia gravis (MG) and thyroid eye disease (TED) are progressing and are on track for topline data readout in the second half of 2024 (MG) and the first half of 2025 (TED). Initial period 1 data from the Phase 2b clinical trial in chronic inflammatory demyelinating polyneuropathy are expected in the second or third quarter of 2024. HanAll Biopharma announced that in collaboration with Immunovant, the Phase 3 clinical study is progressing in generalized myasthenia gravis in Japan. HanAll also reported that a clinical trial notification was approved to initiate a Phase 3 clinical study of batoclimab in TED in Japan. IMVT-1402 Immunovant announced plans to initiate four to five potential registrational programs for IMVT-1402 (second-generation anti-FcRn) during its fiscal year ending March 31, 2025. The company also plans on initiating trials in 10 indications for IMVT-1402 over its next two fiscal years. Immunovant announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 (“the ‘669 patent”) for IMVT-1402. The allowed claims cover composition of matter for the binding sequence of IMVT-1402 to FcRn, method of use of the antibody for treating autoimmune disease, as well as methods for its manufacturing. Not including any potential patent term extension, the ‘669 patent will expire on June 23, 2043. M9140 At the American Association for Cancer Research Annual Meeting, Merck KGaA presented data on M9140, a novel antibody-drug conjugate with topoisomerase 1 inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing tumors.​ M9140 demonstrated high potency, strong antitumor activity and bystander effect in preclinical models. A first-in-human Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical activity of M9140 in patients with advanced solid tumors is ongoing. Acasunlimab Genmab expects to announce acasunlimab (GEN1046: PD-L1 x 4-1BB) Phase 2 data in second-line non-small cell lung cancer (NSCLC) in the first half of 2024. A poster titled “Acasunlimab (duobody-PD-L1x4-1BB) alone or in combination with pembrolizumab in patients with previously treated metastatic non-small cell lung cancer: Initial results of a randomized, open-label, Phase 2 trial” will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 at 9:00 a.m. Central time on Saturday, June 1, 2024. In addition, Genmab plans to initiate a Phase 3 study of acasunlimab in second-line NSCLC in 2024. Sugemalimab CStone announced the National Medical Products Administration of China has approved the supplemental biologics application for sugemalimab (Cejemly®) in combination with fluorouracil and platinum-based chemotherapy as first-line treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma with a PD-L1 expression (Combined Positive Score [CPS] ≥5). Sugemalimab is the first PD-L1 monoclonal antibody approved for this indication. CStone also announced that the results of the progression-free survival final analysis and the overall survival interim analysis in the registrational GEMSTONE-304 study for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma were published in Nature Medicine. OmniAb scientists published a peer-reviewed paper in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional single-domain antibodies (sdAbs). This modality, produced naturally by camelids, has gained popularity as a small, robust and highly versatile building block for antibody discovery, especially in constructing multi-specifics and CAR-T cells. These data supported the feasibility of the Company’s next-generation transgenic chicken OmnidAb™ that produces fully human stabilized sdAbs. The OmnidAb platform was launched during the fourth quarter of 2023. OmniAb will highlight some of its high-throughput single cell screening xPloration™ data at the 20th Annual PEGS Boston Conference and Expo, where Bob Chen, Ph.D., Senior Director, Discovery Systems, will give a presentation titled “Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery” at 12:20 p.m. Eastern time on Wednesday, May 15, 2024. The Company also expects that multiple partners will be presenting data from programs developed with OmniAb technology at the ASCO Annual Meeting taking place May 31 - June 4, 2024. Conference Call and Webcast OmniAb management will host a conference call with accompanying slides today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss this announcement and answer questions. To participate via telephone, please dial (800) 549-8228 using the conference ID 08922. Slides, as well as the live and replay webcast of the call, are available at . About OmniAb® OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes. OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others. For more information, please visit . Forward-Looking Statements OmniAb cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or continue” and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the ability to scale and leverage our business model; the growth prospects of our business; the expected performance and expansion of, our technologies and the opportunities they may create; the ability to add new partners and programs; scientific presentations and clinical and regulatory events of our partners and the timing thereof; the sufficiency of our staffing and resources; expected operating expense and cash runway; and the future balance of cash, cash equivalents and short-term investments. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain; risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; regulatory developments in the United States and foreign countries; unstable market and economic conditions, may have serious adverse consequences on our business, financial condition and stock price; we may use our capital resources sooner than we expect; and other risks described in our prior press releases and filings with the SEC, including under the heading “Risk Factors” in the our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Partner Information The information in this press release regarding partnered products and programs comes from information publicly released by our partners. OMNIAB, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) March 31, 2024 December 31, 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 19,060 $ 16,358 Short-term investments 49,947 70,625 Accounts receivable, net 4,045 3,844 Prepaid expenses and other current assets 3,665 4,074 Total current assets 76,717 94,901 Intangible assets, net 152,055 155,467 Goodwill 83,979 83,979 Property and equipment, net 17,957 18,249 Operating lease right-of-use assets 19,362 19,884 Restricted cash 560 560 Other long-term assets 1,926 2,185 Total assets $ 352,556 $ 375,225 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 3,556 $ 4,411 Accrued expenses and other current liabilities 4,027 7,068 Current contingent liabilities 891 1,303 Current deferred revenue 5,530 6,848 Current operating lease liabilities 3,516 3,486 Total current liabilities 17,520 23,116 Long-term contingent liabilities 3,178 3,203 Deferred income taxes, net 8,737 11,354 Long-term operating lease liabilities 21,418 22,075 Long-term deferred revenue 279 862 Other long-term liabilities 31 30 Total liabilities 51,163 60,640 Stockholders' equity: Preferred stock, $0.0001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock, $0.0001 par value; 1,000,000,000 shares authorized at March 31, 2024 and December 31, 2023; 117,388,789 and 116,859,468 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 12 12 Additional paid-in capital 359,726 353,890 Accumulated other comprehensive (loss) income (17 ) 50 Accumulated deficit (58,328 ) (39,367 ) Total stockholders’ equity 301,393 314,585 Total liabilities and stockholders’ equity $ 352,556 $ 375,225 OMNIAB, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (in thousands, except per share data) Three Months Ended March 31, 2024 2023 Revenues: License and milestone revenue $ 716 $ 12,646 Service revenue 2,766 3,958 Royalty revenue 319 315 Total revenues 3,801 16,919 Operating expenses: Research and development 14,551 13,759 General and administrative 8,337 8,195 Amortization of intangibles 3,412 3,369 Other operating expense, net 54 49 Total operating expenses 26,354 25,372 Loss from operations (22,553 ) (8,453 ) Other income: Interest income 975 1,324 Total other income, net 975 1,324 Loss before income taxes (21,578 ) (7,129 ) Income tax benefit 2,617 1,029 Net loss $ (18,961 ) $ (6,100 ) Net loss per share, basic and diluted $ (0.19 ) $ (0.06 ) Weighted-average shares outstanding, basic and diluted 100,755 99,158